Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1 , Pages 30-37 , January 2008

One-week dose titration of extended release galantamine in patients with Alzheimer’s disease

  • Douglas W. Scharre

      Affiliations

    • Division of Cognitive Neurology, Department of Neurology, Ohio State University, Columbus, OH, USA
    • ,
  • Thomas Shiovitz

      Affiliations

    • California Neuroscience Research, Sherman Oaks, CA, USA
    • ,
  • Young Zhu

      Affiliations

    • Ortho-McNeil Janssen Scientific Affairs, L.L.C., Titusville, NJ, USA
    • ,
  • Joan Amatniek

      Affiliations

    • Ortho-McNeil Janssen Scientific Affairs, L.L.C., Titusville, NJ, USA
    • Corresponding Author InformationCorresponding author. Tel.: 609-730-3438; Fax: 609-730-3406.

References 

  1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122
  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000;
  3. Kaufer DI, Borson S, Kershaw P, Sadik K. Reduction of caregiver burden in Alzheimer’s disease by treatment with galantamine. CNS Spectr. 2005;10:481–488
  4. Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am. 2002;86:657–674
  5. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210–216
  6. Olin J, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2001;(1):CD001747
  7. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Saf. 1998;19:465–480
  8. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, et al. Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1996;277:728–738
  9. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol. 1996;49:1–6
  10. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2003;305:1024–1036
  11. Zhao Q, Janssens L, Verhaeghe T, Brashear HR, Truyen L. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin. 2005;21:1547–1554
  12. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20:120–132
  13. Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clin Ther. 2006;28:365–372
  14. Raskind MA, Peskind ER, Wessel T, Yuan W The Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–2268
  15. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosug Psychiatry. 2001;71:589–595
  16. Wilcock GK, Lilienfeld S, Gaens E Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Br Med J [Clin Res]. 2000;321:1445–1449
  17. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success?. Int J Geriatr Psychiatry. 2001;16:653–666
  18. Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer’s disease assessment scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2001;15:174–183

 Financial disclosures: Douglas W. Scharre, M.D., serves as a consultant and speaker for Abbott Laboratories, Eisai, Inc., Forest Laboratories, Ortho-McNeil Janssen, and Pfizer, Inc. He has received research grants from Astellas Pharma, Inc., Eisai, Inc., Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Myriad Genetics, Inc., Ono Pharmaceutical, Pfizer, Inc., Sanofi-Aventis Pharmaceuticals, and Voyager. Thomas Shiovitz, M.D., serves as a consultant and speaker for Pfizer, Inc. He has received research grants from Astellas Pharma, Inc., Astra-Zeneca, Corcept, Eisai, Inc., Janssen Pharmaceutica, Lilly, Merck, Pfizer, Inc., Sanofi-Aventis Pharmaceuticals, and Sention. Young Zhu, Ph.D., and Joan Amatniek, M.D., are employees of Ortho-McNeil Janssen Scientific Affairs, L.L.C.

PII: S1552-5260(07)00638-3

doi: 10.1016/j.jalz.2007.10.013

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1 , Pages 30-37 , January 2008

Article Tools

* Image Usage & Resolution